Investor Moves
| Investor | Portfolio Value | Portfolio Change | Position Change | Avg Buy Price | Current Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $-497.8K ExitQ4 2025 $498k -- -- | |||||
Ken GriffinCitadel Advisors $-93.4K TrimQ3 2025 $93k -- -- | |||||
News
globenewswire.comJyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interviewglobenewswire.comMay 29
globenewswire.comJyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025globenewswire.comMay 15
globenewswire.comJyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025globenewswire.comMay 15
globenewswire.comJyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolioglobenewswire.comApr 28
defenseworld.netJyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in Marchdefenseworld.netMar 29